CERo TherapeuticsCERO
About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more capital invested
Capital invested by funds: $318K [Q3] → $956K (+$638K) [Q4]
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
18% more funds holding
Funds holding: 17 [Q3] → 20 (+3) [Q4]
0.31% more ownership
Funds ownership: 6.64% [Q3] → 6.95% (+0.31%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CERO.
Financial journalist opinion
Based on 4 articles about CERO published over the past 30 days









